paroxetine has been researched along with Mental Disorders in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (29.79) | 18.2507 |
| 2000's | 22 (46.81) | 29.6817 |
| 2010's | 10 (21.28) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Konstantinou, G; Mylona, S; Paschalakis, G; Stavrinou, A; Vasilopoulou, P | 1 |
| Bianchi, L; Del Duca, E; Esposito, M; Fargnoli, MC; Giunta, A; Manfreda, V; Troisi, A | 1 |
| Bellini, M; Bertani, L; Blandizzi, C; Caserta, A; Cortopassi, S; de Bortoli, N; Dell'Osso, L; Fani, B; Gambaccini, D; Marchi, S; Nisita, C; Pancetti, A; Salvadori, S; Stasi, C | 1 |
| Betti, L; Bonuccelli, U; Ceravolo, R; Giannaccini, G; Kiferle, L; Mazzucchi, S; Palego, L; Palermo, G; Unti, E | 1 |
| Arnold, PD; Bousman, C; Greenslade, A; Maruf, AA | 1 |
| Gorman, DA; Lam, D; Patten, S; Pringsheim, T | 1 |
| Ballesteros-Zebadua, P; Franco-Perez, J; Manjarrez-Marmolejo, J | 1 |
| Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T | 1 |
| Gupta, MA | 1 |
| Carson, HJ; Eilers, SG | 1 |
| Freeman, MP | 1 |
| Ham, BJ; Han, C; Marks, DM; Masand, PS; Pae, CU; Park, MH; Patkar, AA | 1 |
| Dubois, O | 1 |
| Carpenter, DJ; Davies, JT; Fong, R; Kraus, JE; Moore, C; Thase, ME | 1 |
| Andrade, C | 1 |
| Anderson, TA; Dobscha, SK; Hauser, P; Hoffman, WF; Snodgrass, LS; Turner, EH; Winterbottom, LM | 1 |
| Biederman, J; Carpenter, D; Emslie, G; Farrell, C; Geller, DA; Mullin, B; Stewart, SE; Wagner, KD | 1 |
| Akiyama, K; Hirokane, G; Morita, S; Okawa, M; Shimoda, K; Ueda, M; Watanabe, T | 1 |
| Einarson, A | 1 |
| Hallberg, P; Odlind, V; Sjöblom, V | 1 |
| Begley, AE; Dew, MA; Houck, PR; Mazumdar, S; Mulsant, BH; Reynolds, CF; Scott, J; Tang, G | 1 |
| Pae, CU; Patkar, AA | 1 |
| Brown, M; Clark, RF; Gray, AJ; Guo, Z; Halagappa, VM; Iyun, T; Martin, B; Matsuoka, Y; Mattson, MP; Maudsley, S; Nelson, RL; Pearson, M | 1 |
| Alfirevic, Z; Degoricija, V; Vucicevic, Z; Vukicevic-Badouin, D | 1 |
| Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G | 1 |
| Alexander, T; Ances, BM; Ellis, RJ; Letendre, SL | 1 |
| Helmeste, D; Tang, SW | 1 |
| Bloch, M; Braun, AR; Rubinow, DR; Stager, SV | 1 |
| Alpert, JE; Fava, M; Maddocks, A; Rosenbaum, JF | 1 |
| Mitchell, S; Tracy, KA; Zajecka, J | 1 |
| Harry, B; Zimmerschied, JA | 1 |
| Hengeveld, MW; Tuyl, JP; Van der Mast, RC; Van Kempen, GM; Verkes, RJ; Zwinderman, AH | 1 |
| Stahl, SM | 1 |
| Carlson, J; Dahlöf, P; Ejnell, H; Hedner, J; Kraiczi, H | 1 |
| Weeks, SM; Westlake, RJ | 1 |
| Draper, B; Meares, S | 1 |
| Bell, C; Nutt, D | 1 |
| Liebowitz, MR | 1 |
| Hensley, PL; Nurnberg, HG; Paine, SS; Thompson, PM | 1 |
| Hensley, PL; Nurnberg, HG; Thompson, PM | 1 |
| Amsterdam, J; Apter, J; Fava, M; Londborg, P; Michelson, D; Tamura, R; Tepner, RG | 1 |
| Daniels, S | 1 |
| Bourin, M; Chue, P; Guillon, Y | 1 |
| Armani, A; Baroni, S; Cassano, GB; Dell'Osso, L; Di Nasso, E; Giannaccini, G; Lucacchini, A; Marazziti, D; Masala, I; Rossi, A | 1 |
| Cipriani, R; Perini, GI; Rampinelli, S | 1 |
| Cheer, SM; Goa, KL; Matheson, AJ; Ormrod, D; Wagstaff, AJ | 1 |
| Dam, H; Lauritzen, L; Mellerup, ET; Plenge, P | 1 |
12 review(s) available for paroxetine and Mental Disorders
| Article | Year |
|---|---|
Antidepressant pharmacogenetics in children and young adults: A systematic review.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mental Disorders; Nortriptyline; Paroxetine; Pharmacogenetics; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tryptophan Hydroxylase; Venlafaxine Hydrochloride; Young Adult | 2019 |
Chronic paroxetine treatment: effects on other non-serotonergic neurotransmitter systems.
Topics: Animals; Brain; Drug Administration Schedule; Humans; Mental Disorders; Neurotransmitter Agents; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2013 |
Paroxetine: safety and tolerability issues.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Child; Clinical Trials as Topic; Delayed-Action Preparations; Drug Interactions; Female; Humans; Mental Disorders; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors | 2008 |
[Indications for crenotherapy].
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Asthenia; Balneology; Complementary Therapies; Depressive Disorder; Humans; Mental Disorders; Multicenter Studies as Topic; Paroxetine; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Somatoform Disorders | 2009 |
Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Suicide; Young Adult | 2011 |
Paroxetine: current status in psychiatry.
Topics: Humans; Mental Disorders; Paroxetine; Psychiatry; Selective Serotonin Reuptake Inhibitors | 2007 |
Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders.
Topics: Antiretroviral Therapy, Highly Active; Brain; Citalopram; Cognition Disorders; HIV Infections; Humans; Lithium Carbonate; Mental Disorders; Paroxetine; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Valproic Acid | 2008 |
Paroxetine.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Mental Disorders; Paroxetine; Risk; Selective Serotonin Reuptake Inhibitors; Suicide | 2008 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Female; Fluoxetine; Fluvoxamine; Headache; Humans; Infant; Infant, Newborn; Male; MEDLINE; Mental Disorders; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensation Disorders; Sertraline; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 1997 |
Update on the diagnosis and treatment of social anxiety disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Diagnosis, Differential; Female; Humans; Male; Mental Disorders; Mood Disorders; Paroxetine; Phobic Disorders; Quality of Life; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Paroxetine: a review.
Topics: Animals; Antidepressive Agents, Second-Generation; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
Paroxetine: an update of its use in psychiatric disorders in adults.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Comorbidity; Half-Life; Humans; Intestinal Absorption; Mental Disorders; Middle Aged; Paroxetine; Psychomotor Performance; Treatment Outcome | 2002 |
9 trial(s) available for paroxetine and Mental Disorders
| Article | Year |
|---|---|
Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
Topics: Adult; Aripiprazole; Asian People; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Electrocardiography; Electroencephalography; Female; Genotype; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Piperazines; Quinolones | 2014 |
Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
Topics: Adolescent; Child; Comorbidity; Double-Blind Method; Female; Humans; Male; Mental Disorders; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Recurrence; Selective Serotonin Reuptake Inhibitors | 2003 |
The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients.
Topics: Adult; Aged; Analysis of Variance; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Mental Disorders; Middle Aged; Paroxetine; Regression Analysis; Selective Serotonin Reuptake Inhibitors | 2006 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imipramine; Male; Mental Disorders; Middle Aged; Paroxetine; Personality Development; Phobic Disorders; Recurrence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression.
Topics: Adult; Anger; Depression; Double-Blind Method; Female; Humans; Male; Mental Disorders; Paroxetine; Patient Dropouts; Personality Disorders; Placebos; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Treatment Outcome | 1998 |
Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea.
Topics: Adult; Aged; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Polysomnography; Psychiatric Status Rating Scales; Respiration; Selective Serotonin Reuptake Inhibitors; Sleep Apnea Syndromes; Sleep, REM | 1999 |
Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Medical Records; Mental Disorders; Middle Aged; Mood Disorders; Paroxetine; Retrospective Studies; Sampling Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Fluoxetine; Humans; Male; Mental Disorders; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2000 |
Paroxetine in alopecia areata.
Topics: Adult; Alopecia Areata; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
26 other study(ies) available for paroxetine and Mental Disorders
| Article | Year |
|---|---|
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.
Topics: Basal Ganglia; Basal Ganglia Diseases; Calcinosis; Depression; Diagnosis, Differential; Female; Humans; Mental Disorders; Middle Aged; Neurodegenerative Diseases; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Psychotropic Drugs; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series.
Topics: Adult; Agoraphobia; Antibodies, Monoclonal, Humanized; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Lithium Carbonate; Male; Mental Disorders; Middle Aged; Nordazepam; Panic Disorder; Paroxetine; Psoriasis; Quetiapine Fumarate; Severity of Illness Index; Treatment Outcome; Valproic Acid | 2020 |
The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment.
Topics: Adult; Aged; Female; Humans; Irritable Bowel Syndrome; Longitudinal Studies; Male; Mental Disorders; Middle Aged; Paroxetine; Prospective Studies; Quality of Life; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms.
Topics: Aged; Aged, 80 and over; Anger; Blood Platelets; Brain-Derived Neurotrophic Factor; Cognition Disorders; Female; Humans; Huntington Disease; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Paroxetine; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Social Perception; Voice | 2018 |
The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents; Canada; Child; Child, Preschool; Citalopram; Databases, Factual; Fluoxetine; Fluvoxamine; Humans; Infant; Mental Disorders; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Sertraline | 2013 |
Suicide attempt and externalizing behaviours in posttraumatic stress disorder (PTSD): possible role of the activating effect of antidepressants.
Topics: Adult; Female; Humans; Mental Disorders; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic; Suicide, Attempted | 2015 |
Death from undiagnosed glioblastoma multiforme and toxic self-medication presenting with concurrent dysfunctional behavior.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Brain Edema; Brain Neoplasms; Dextropropoxyphene; Female; Forensic Pathology; Forensic Toxicology; Glioblastoma; Headache Disorders, Secondary; Humans; Hydrocodone; Intracranial Hemorrhages; Mental Disorders; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self Medication; Vitreous Body | 2008 |
Reproductive neuroscience: biology, environment, and clinical implications in women's mental health.
Topics: Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Genotype; Humans; Mental Disorders; Middle Aged; Paroxetine; Perimenopause; Reproductive Medicine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Social Environment; Stress Disorders, Post-Traumatic | 2008 |
Odd odds.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Mental Disorders; Paroxetine; Randomized Controlled Trials as Topic; Suicide | 2011 |
Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Topics: Citalopram; Clinical Pharmacy Information Systems; Cost Control; Cost Savings; Drug Administration Schedule; Drug Costs; Drug Utilization; Fluoxetine; Fluvoxamine; Hospital Costs; Hospitals, Veterans; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2003 |
Abrupt discontinuation of psychotropic drugs following confirmation of pregnancy: a risky practice.
Topics: Adult; Antidepressive Agents, Second-Generation; Counseling; Depression, Postpartum; Female; Humans; Mental Disorders; Paroxetine; Pregnancy; Pregnancy Complications; Psychotropic Drugs; Risk Factors; Substance Withdrawal Syndrome; Teratogens | 2005 |
Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn.
Topics: Abnormalities, Drug-Induced; Confounding Factors, Epidemiologic; Female; Heart Defects, Congenital; Humans; Infant, Newborn; Mental Disorders; Paroxetine; Persistent Fetal Circulation Syndrome; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors | 2006 |
Statistical analysis of longitudinal psychiatric data with dropouts.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Humans; Likelihood Functions; Longitudinal Studies; Mental Disorders; Nortriptyline; Paroxetine; Patient Dropouts; Randomized Controlled Trials as Topic; Regression Analysis | 2007 |
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.
Topics: Alzheimer Disease; Amygdala; Amyloid beta-Peptides; Animals; Avoidance Learning; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Female; Hippocampus; Male; Maze Learning; Mental Disorders; Mice; Mice, Transgenic; Motor Activity; Paroxetine; Peptide Fragments; Selective Serotonin Reuptake Inhibitors; Swimming; Tauopathies | 2007 |
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Edema; Fatal Outcome; Fluphenazine; Haloperidol; Heart Arrest; Humans; Hyperglycemia; Hyponatremia; Inappropriate ADH Syndrome; Male; Mental Disorders; Olanzapine; Pancreatitis; Paroxetine; Polypharmacy; Selective Serotonin Reuptake Inhibitors | 2007 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Utilization Review; Female; Fluoxetine; Humans; Hyperprolactinemia; Italy; Male; Medical Records; Mental Disorders; Olanzapine; Paroxetine; Practice Patterns, Physicians'; Retrospective Studies; Risperidone; Sertraline; Treatment Outcome | 2008 |
Severe psychiatric symptoms associated with paroxetine withdrawal.
Topics: Adult; Behavior; Controlled Clinical Trials as Topic; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Stuttering; Substance Withdrawal Syndrome | 1995 |
Serotonin syndrome in a prisoner.
Topics: Antidepressive Agents, Second-Generation; Ataxia; Confusion; Depression; Drug Interactions; Forensic Psychiatry; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Prisoners; Psychotropic Drugs; Risk Factors; Selective Serotonin Reuptake Inhibitors; Syndrome | 1998 |
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
Topics: Adolescent; Adult; Child; Citalopram; Cytochrome P-450 Enzyme System; Drug Prescriptions; Fluoxetine; Fluvoxamine; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Pathological jealousy appearing after cerebrovascular infarction in a 25-year-old woman.
Topics: Adult; Cerebrovascular Disorders; Female; Humans; Jealousy; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; Humans; Mental Disorders; Noise; Nursing Homes; Paroxetine; Patient Compliance; Physical Therapy Modalities; Psychomotor Agitation; Restraint, Physical; Risperidone; Verbal Behavior | 1999 |
Paroxetine and its uses in psychiatry.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depression; Drug Interactions; Humans; Mental Disorders; Obsessive-Compulsive Disorder; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders | 1999 |
Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
Topics: Dose-Response Relationship, Drug; Fluoxetine; Follow-Up Studies; Humans; Mental Disorders; Mental Health Services; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1999 |
Drug treatment for resistant depression.
Topics: Bias; Cyclohexanols; Drug Resistance; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2000 |
Decreased platelet [3H]paroxetine binding sites in suicide attempters.
Topics: Adolescent; Adult; Bipolar Disorder; Carrier Proteins; Comorbidity; Depressive Disorder; Female; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Radioligand Assay; Receptors, Drug; Risk Factors; Serotonin Plasma Membrane Transport Proteins; Suicide, Attempted | 2001 |
Platelet 3H-imipramine and 3H-paroxetine binding during treatment with psychoactive drugs.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Female; Humans; Imipramine; Male; Mental Disorders; Middle Aged; Paroxetine; Piperidines; Psychotropic Drugs; Radioligand Assay; Serotonin Antagonists | 1991 |